459 related articles for article (PubMed ID: 17785545)
1. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
Kelland L
Clin Cancer Res; 2007 Sep; 13(17):4960-3. PubMed ID: 17785545
[TBL] [Abstract][Full Text] [Related]
2. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
Tárkányi I; Aradi J
Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
[TBL] [Abstract][Full Text] [Related]
5. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS
Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619
[TBL] [Abstract][Full Text] [Related]
6. Targeting telomeres and telomerase.
De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
[TBL] [Abstract][Full Text] [Related]
7. Telomeres as targets for anticancer therapies.
Folini M; Venturini L; Cimino-Reale G; Zaffaroni N
Expert Opin Ther Targets; 2011 May; 15(5):579-93. PubMed ID: 21288186
[TBL] [Abstract][Full Text] [Related]
8. Telomere biology of pediatric cancer.
Tabori U; Dome JS
Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
[TBL] [Abstract][Full Text] [Related]
9. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells.
Gomez-Millan J; Goldblatt EM; Gryaznov SM; Mendonca MS; Herbert BS
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):897-905. PubMed ID: 17175117
[TBL] [Abstract][Full Text] [Related]
10. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
Raymond E; Faivre S; Dieras V; Von Hoff D
Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
[TBL] [Abstract][Full Text] [Related]
11. Ageing and cancer: the telomere and telomerase connection.
Shay JW; Wright WE
Novartis Found Symp; 2001; 235():116-25; discussion 125-9, 146-9. PubMed ID: 11280022
[TBL] [Abstract][Full Text] [Related]
12. [siRNA targeting telomerase--effective tool in anti-cancer therapy?].
Rubiś B; Półrolniczak A; Rybczyńska M
Postepy Biochem; 2008; 54(4):384-92. PubMed ID: 19248585
[TBL] [Abstract][Full Text] [Related]
13. Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance.
Cerone MA; Londoño-Vallejo JA; Autexier C
Oncogene; 2006 Nov; 25(56):7411-20. PubMed ID: 16767163
[TBL] [Abstract][Full Text] [Related]
14. Determination of telomerase activity and telomere length.
Wu KD; Moore MA
Methods Mol Med; 2005; 113():207-23. PubMed ID: 15968105
[TBL] [Abstract][Full Text] [Related]
15. Correlation of telomerase activity and telomere length to chemosensitivity.
Kiyozuka Y
Methods Mol Med; 2005; 111():97-108. PubMed ID: 15911975
[TBL] [Abstract][Full Text] [Related]
16. Telomerase inhibitors in cancer therapy: current status and future directions.
Incles CM; Schultes CM; Neidle S
Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
[TBL] [Abstract][Full Text] [Related]
17. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia.
Sumi M; Tauchi T; Sashida G; Nakajima A; Gotoh A; Shin-Ya K; Ohyashiki JH; Ohyashiki K
Int J Oncol; 2004 Jun; 24(6):1481-7. PubMed ID: 15138591
[TBL] [Abstract][Full Text] [Related]
18. The many faces of telomerase: emerging extratelomeric effects.
Bollmann FM
Bioessays; 2008 Aug; 30(8):728-32. PubMed ID: 18623070
[TBL] [Abstract][Full Text] [Related]
19. G-quadruplex stabilizer 3,6-bis(1-methyl-4-vinylpyridinium)carbazole diiodide induces accelerated senescence and inhibits tumorigenic properties in cancer cells.
Huang FC; Chang CC; Lou PJ; Kuo IC; Chien CW; Chen CT; Shieh FY; Chang TC; Lin JJ
Mol Cancer Res; 2008 Jun; 6(6):955-64. PubMed ID: 18515756
[TBL] [Abstract][Full Text] [Related]
20. Role of telomeres and telomerase in the pathogenesis of human cancer.
Hahn WC
J Clin Oncol; 2003 May; 21(10):2034-43. PubMed ID: 12743159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
